OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer

First Orphan Drug Designation for OBI-888, a novel first-in-class Monoclonal Antibody targeting Globo H, a glycolipid antigen found on multiple tumor types. TAIPEI, Taiwan, November 21, 2018 /PRNewswire/ — OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for OBI-888 for […]